Arbutus Biopharma Corp ABUS

About Arbutus Biopharma Corp (ABUS): stock profile, AI score and financials

Arbutus Biopharma Corp (ABUS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABUS at 14.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,823 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Arbutus Biopharma Corp reports quarterly revenue of $1.0M, net income of $-5.1M. Top institutional holders of ABUS by reported 13-F value include Two Seas Capital, MORGAN STANLEY, Whitefort Capital Management, based on the most recent SEC filings. ABUS trades on the Nasdaq exchange and files with the SEC under CIK 1447028. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arbutus Biopharma Corp directly from SEC EDGAR.

SEC EDGAR: CIK 1447028 →